Sanofi and Immunocore Pair High Potential Molecules for Metastatic Skin Cancers

On Friday, Immunocore and Sanofi announced a clinical trial collaboration and supply deal. Under the deal, Sanofi will study its SAR444245 in combination with Immunocore’s KIMMTRAK in HLA-A*02:01 positive patients with advanced unresectable or metastatic skin cancers in an ongoing Phase I/II trial.